4D Molecular Therapeutics, Inc. (FDMT)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration and license revenue | 15 | 14 | 3 | |
| Research and development | 47,951 | 40,699 | 38,484 | |
| General and administrative | 11,520 | 12,936 | 12,651 | |
| Total operating expenses | 59,471 | 53,635 | 51,135 | |
| Loss from operations | -59,456 | -53,621 | -51,132 | |
| Other income (expense), net | -61 | 67 | -1 | |
| Interest income | 4,859 | 5,582 | 7,290 | |
| Total other income, net | 4,798 | 5,649 | 7,289 | |
| Net loss | -54,658 | -47,972 | -43,843 | |
| Earnings per share, basic | -0.98 | -0.86 | -0.79 | |
| Earnings per share, diluted | -0.98 | -0.86 | -0.79 | |
| Weighted average number of shares outstanding, basic | 55,927,091 | 55,744,047 | 55,554,476 | |
| Weighted average number of shares outstanding, diluted | 55,927,091 | 55,744,047 | 55,554,476 | |